Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes.

Frazao A, Messaoudene M, Nunez N, Dulphy N, Roussin F, Sedlik C, Zitvogel L, Piaggio E, Toubert A, Caignard A.

Cancer Immunol Res. 2018 Dec 4. doi: 10.1158/2326-6066.CIR-18-0085. [Epub ahead of print]

PMID:
30514793
2.

Retinal Neuronal Loss in Visually Asymptomatic Patients With Myoclonic Epilepsy With Ragged-Red Fibers.

Najjar RP, Reynier P, Caignard A, Procaccio V, Amati-Bonneau P, Mack H, Milea D.

J Neuroophthalmol. 2018 Jul 3. doi: 10.1097/WNO.0000000000000690. [Epub ahead of print]

PMID:
29979334
3.

[Topical anesthesia without the use of an anesthesiologist in adult outpatient cataract surgery: Assessment of selection criteria on consultation, report of 248 cases].

Pepin M, Rineau E, Caignard A, Leruez S, Gohier P.

J Fr Ophtalmol. 2018 May;41(5):441-446. doi: 10.1016/j.jfo.2017.11.015. French.

PMID:
29776768
4.

Increased steroidogenesis promotes early-onset and severe vision loss in females with OPA1 dominant optic atrophy.

Sarzi E, Seveno M, Angebault C, Milea D, Rönnbäck C, Quilès M, Adrian M, Grenier J, Caignard A, Lacroux A, Lavergne C, Reynier P, Larsen M, Hamel CP, Delettre C, Lenaers G, Müller A.

Hum Mol Genet. 2017 Dec 1;26(23):4764. doi: 10.1093/hmg/ddx376. No abstract available.

PMID:
29045675
5.

TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.

Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L.

Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018.

6.

Tumor-Derived Mesenchymal Stem Cells Use Distinct Mechanisms to Block the Activity of Natural Killer Cell Subsets.

Galland S, Vuille J, Martin P, Letovanec I, Caignard A, Fregni G, Stamenkovic I.

Cell Rep. 2017 Sep 19;20(12):2891-2905. doi: 10.1016/j.celrep.2017.08.089.

7.

[Wolfram syndrome and juvenile glaucoma: Case report].

de Saint-Martin G, Caignard A, Dureau P, Leruez S.

J Fr Ophtalmol. 2017 Oct;40(8):e297-e298. doi: 10.1016/j.jfo.2017.05.006. Epub 2017 Sep 15. French. No abstract available.

PMID:
28919187
8.

Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers.

Messaoudene M, Frazao A, Gavlovsky PJ, Toubert A, Dulphy N, Caignard A.

Front Immunol. 2017 Jun 12;8:683. doi: 10.3389/fimmu.2017.00683. eCollection 2017.

9.

Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.

Frazao A, Colombo M, Fourmentraux-Neves E, Messaoudene M, Rusakiewicz S, Zitvogel L, Vivier E, Vély F, Faure F, Dréno B, Benlalam H, Bouquet F, Savina A, Pasmant E, Toubert A, Avril MF, Caignard A.

Cancer Immunol Res. 2017 Jul;5(7):582-593. doi: 10.1158/2326-6066.CIR-16-0380. Epub 2017 Jun 2.

10.

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, Iribarren C, Cremer I, Marabelle A, Borg C, Semeraro M, Barraud L, Limacher JM, Eggermont A, Kroemer G, Zitvogel L.

Oncoimmunology. 2016 May 13;6(1):e1163456. doi: 10.1080/2162402X.2016.1163456. eCollection 2017.

11.

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L.

Oncoimmunology. 2016 Apr 25;6(1):e1137418. doi: 10.1080/2162402X.2015.1137418. eCollection 2017.

12.

NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.

Messaoudene M, Fregni G, Enot D, Jacquelot N, Neves E, Germaud N, Garchon HJ, Boukouaci W, Tamouza R, Chanal J, Avril MF, Toubert A, Zitvogel L, Rusakiewicz S, Caignard A.

Oncoimmunology. 2016 Mar 10;5(12):e1154251. doi: 10.1080/2162402X.2016.1154251. eCollection 2016.

13.

Immune Modifications in Fetal Membranes Overlying the Cervix Precede Parturition in Humans.

Marcellin L, Schmitz T, Messaoudene M, Chader D, Parizot C, Jacques S, Delaire J, Gogusev J, Schmitt A, Lesaffre C, Breuiller-Fouché M, Caignard A, Vaiman D, Goffinet F, Cabrol D, Gorochov G, Méhats C.

J Immunol. 2017 Feb 1;198(3):1345-1356. doi: 10.4049/jimmunol.1601482. Epub 2016 Dec 28.

14.

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.

Rocca YS, Roberti MP, Juliá EP, Pampena MB, Bruno L, Rivero S, Huertas E, Sánchez Loria F, Pairola A, Caignard A, Mordoh J, Levy EM.

Front Immunol. 2016 Oct 10;7:413. eCollection 2016.

15.

Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.

Felix J, Cassinat B, Porcher R, Schlageter MH, Maubec E, Pages C, Baroudjian B, Homyrda L, Boukouaci W, Tamouza R, Bagot M, Caignard A, Toubert A, Lebbé C, Moins-Teisserenc H.

Int Immunopharmacol. 2016 Nov;40:466-473. doi: 10.1016/j.intimp.2016.09.030. Epub 2016 Oct 8.

PMID:
27728898
16.

[Neuro-ophthalmic emergencies].

Caignard A, Leruez S, Milea D.

J Fr Ophtalmol. 2016 Oct;39(8):716-728. doi: 10.1016/j.jfo.2016.05.003. Epub 2016 Sep 14. Review. French.

17.

Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response.

Felix J, Lambert J, Roelens M, Maubec E, Guermouche H, Pages C, Sidina I, Cordeiro DJ, Maki G, Chasset F, Porcher R, Bagot M, Caignard A, Toubert A, Lebbé C, Moins-Teisserenc H.

Oncoimmunology. 2016 Feb 18;5(7):1136045. doi: 10.1080/2162402X.2015.1136045. eCollection 2016 Jul.

18.

Increased steroidogenesis promotes early-onset and severe vision loss in females with OPA1 dominant optic atrophy.

Sarzi E, Seveno M, Angebault C, Milea D, Rönnbäck C, Quilès M, Adrian M, Grenier J, Caignard A, Lacroux A, Lavergne C, Reynier P, Larsen M, Hamel CP, Delettre C, Lenaers G, Müller A.

Hum Mol Genet. 2016 Jun 15;25(12):2539-2551. Epub 2016 Jun 3. Erratum in: Hum Mol Genet. 2017 Dec 1;26(23):4764.

PMID:
27260406
19.

Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells.

Dulphy N, Chrétien AS, Khaznadar Z, Fauriat C, Nanbakhsh A, Caignard A, Chouaib S, Olive D, Toubert A.

Front Immunol. 2016 Mar 9;7:94. doi: 10.3389/fimmu.2016.00094. eCollection 2016. Review.

20.

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, Yamazaki T, Roberti MP, Daillère R, Vétizou M, Poirier-Colame V, Semeraro M, Caignard A, Slingluff CL Jr, Sallusto F, Rusakiewicz S, Weide B, Marabelle A, Kohrt H, Dalle S, Cavalcanti A, Kroemer G, Di Giacomo AM, Maio M, Wong P, Yuan J, Wolchok J, Umansky V, Eggermont A, Zitvogel L.

J Clin Invest. 2016 Mar 1;126(3):921-37. doi: 10.1172/JCI80071. Epub 2016 Feb 8.

21.

Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.

Messaoudene M, Périer A, Fregni G, Neves E, Zitvogel L, Cremer I, Chanal J, Sastre-Garau X, Deschamps L, Marinho E, Larousserie F, Maubec E, Avril MF, Caignard A.

PLoS One. 2015 Jul 28;10(7):e0133363. doi: 10.1371/journal.pone.0133363. eCollection 2015.

22.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

23.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

24.

When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma.

Messaoudene M, Avril MF, Caignard A.

Oncoimmunology. 2014 Feb 14;3:e28048. eCollection 2014.

25.

Improved locus-specific database for OPA1 mutations allows inclusion of advanced clinical data.

Ferré M, Caignard A, Milea D, Leruez S, Cassereau J, Chevrollier A, Amati-Bonneau P, Verny C, Bonneau D, Procaccio V, Reynier P.

Hum Mutat. 2015 Jan;36(1):20-5. doi: 10.1002/humu.22703. Epub 2014 Dec 1.

PMID:
25243597
26.

Obesity and renal cancer: Role of adipokines in the tumor-immune system conflict.

Gati A, Kouidhi S, Marrakchi R, El Gaaied A, Kourda N, Derouiche A, Chebil M, Caignard A, Perier A.

Oncoimmunology. 2014 Jan 1;3(1):e27810. Epub 2014 Jan 16. Review.

27.

Optic nerve and visual pathways primary glioblastoma treated with radiotherapy and temozolomide chemotherapy.

Caignard A, Faguer R, Mercier P, Menei P, Milea D.

Eur J Ophthalmol. 2014 Jul-Aug;24(4):637-40. doi: 10.5301/ejo.5000416. Epub 2013 Dec 13.

PMID:
24366773
28.

Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma.

Messaoudene M, Fregni G, Fourmentraux-Neves E, Chanal J, Maubec E, Mazouz-Dorval S, Couturaud B, Girod A, Sastre-Garau X, Albert S, Guédon C, Deschamps L, Mitilian D, Cremer I, Jacquelot N, Rusakiewicz S, Zitvogel L, Avril MF, Caignard A.

Cancer Res. 2014 Jan 1;74(1):81-92. doi: 10.1158/0008-5472.CAN-13-1303. Epub 2013 Nov 13.

29.

Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages.

Fregni G, Messaoudene M, Fourmentraux-Neves E, Mazouz-Dorval S, Chanal J, Maubec E, Marinho E, Scheer-Senyarich I, Cremer I, Avril MF, Caignard A.

PLoS One. 2013 Oct 18;8(10):e76928. doi: 10.1371/journal.pone.0076928. eCollection 2013.

30.

Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.

Romero AI, Chaput N, Poirier-Colame V, Rusakiewicz S, Jacquelot N, Chaba K, Mortier E, Jacques Y, Caillat-Zucman S, Flament C, Caignard A, Messaoudene M, Aupérin A, Vielh P, Dessen P, Porta C, Mateus C, Ayyoub M, Valmori D, Eggermont A, Robert C, Zitvogel L.

Cancer Res. 2014 Jan 1;74(1):68-80. doi: 10.1158/0008-5472.CAN-13-1186. Epub 2013 Nov 6.

31.

Expression of IL-27 by tumor cells in invasive cutaneous and metastatic melanomas [corrected]..

Gonin J, Carlotti A, Dietrich C, Audebourg A, Radenen-Bussière B, Caignard A, Avril MF, Vacher-Lavenu MC, Larousserie F, Devergne O.

PLoS One. 2013 Oct 10;8(10):e75694. doi: 10.1371/journal.pone.0075694. eCollection 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/e1a0e85e-e632-40f2-9925-e0b71eb18b56.

32.

Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.

Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, Cremer I, Caignard A, Poirier-Colame V, Chaba K, Flament C, Halama N, Jäger D, Eggermont A, Bonvalot S, Commo F, Terrier P, Opolon P, Emile JF, Coindre JM, Kroemer G, Chaput N, Le Cesne A, Blay JY, Zitvogel L.

Cancer Res. 2013 Jun 15;73(12):3499-510. doi: 10.1158/0008-5472.CAN-13-0371. Epub 2013 Apr 16.

33.

High number of CD56(bright) NK-cells and persistently low CD4+ T-cells in a hemophiliac HIV/HCV co-infected patient without opportunistic infections.

Fregni G, Maresca AF, Jalbert V, Caignard A, Scott-Algara D, Cramer EB, Rouveix E, Béné MC, Capron C.

Virol J. 2013 Jan 26;10:33. doi: 10.1186/1743-422X-10-33.

34.

NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies.

Fregni G, Perier A, Avril MF, Caignard A.

Oncoimmunology. 2012 Jan 1;1(1):38-47.

35.

Interleukin-15 plays a central role in human kidney physiology and cancer through the γc signaling pathway.

Giron-Michel J, Azzi S, Khawam K, Mortier E, Caignard A, Devocelle A, Ferrini S, Croce M, François H, Lecru L, Charpentier B, Chouaib S, Azzarone B, Eid P.

PLoS One. 2012;7(2):e31624. doi: 10.1371/journal.pone.0031624. Epub 2012 Feb 21.

36.

Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer.

Allard M, Oger R, Vignard V, Percier JM, Fregni G, Périer A, Caignard A, Charreau B, Bernardeau K, Khammari A, Dréno B, Gervois N.

PLoS One. 2011;6(6):e21118. doi: 10.1371/journal.pone.0021118. Epub 2011 Jun 21.

37.

Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions.

Nardin A, Wong WC, Tow C, Molina TJ, Tissier F, Audebourg A, Garcette M, Caignard A, Avril MF, Abastado JP, Prévost-Blondel A.

J Invest Dermatol. 2011 Sep;131(9):1896-905. doi: 10.1038/jid.2011.128. Epub 2011 Jun 9.

38.

Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal cancer.

Giron-Michel J, Azzi S, Khawam K, Caignard A, Devocelle A, Perrier A, Chouaib S, Eid P, Azzarone B.

Bull Cancer. 2011 May;98(5):32-9. doi: 10.1684/bdc.2011.1359.

39.

Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.

Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, Escudier B, Azzarone B, Caignard A.

Oncogene. 2011 Jun 9;30(23):2622-32. doi: 10.1038/onc.2010.638. Epub 2011 Jan 24.

PMID:
21258414
40.

Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy.

Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, Gervois N, Allard M, Bercovici N, Avril MF, Caignard A.

Clin Cancer Res. 2011 May 1;17(9):2628-37. doi: 10.1158/1078-0432.CCR-10-2084. Epub 2011 Jan 11.

41.

Cytokeratin 18 expression pattern correlates with renal cell carcinoma progression: relationship with Snail.

Messai Y, Noman MZ, Derouiche A, Kourda N, Akalay I, Hasmim M, Stasik I, Ben Jilani S, Chebil M, Caignard A, Azzarone B, Gati A, Ben Ammar Elgaaied A, Chouaib S.

Int J Oncol. 2010 May;36(5):1145-54.

PMID:
20372788
42.

Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients.

Pittari G, Fregni G, Roguet L, Garcia A, Vataire AL, Wittnebel S, Amsellem S, Chouaib S, Bourhis JH, Caignard A.

Bone Marrow Transplant. 2010 May;45(5):862-71. doi: 10.1038/bmt.2009.265. Epub 2009 Oct 5.

PMID:
19802033
43.

[The controversial memory of natural killer cells?].

Bercovici N, Caignard A.

Med Sci (Paris). 2009 Jun-Jul;25(6-7):559-62. doi: 10.1051/medsci/2009256-7559. French. No abstract available.

44.

Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition.

Khawam K, Giron-Michel J, Gu Y, Perier A, Giuliani M, Caignard A, Devocelle A, Ferrini S, Fabbi M, Charpentier B, Ludwig A, Chouaib S, Azzarone B, Eid P.

Cancer Res. 2009 Feb 15;69(4):1561-9. doi: 10.1158/0008-5472.CAN-08-3198. Epub 2009 Feb 3.

45.

Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation.

Pallandre JR, Krzewski K, Bedel R, Ryffel B, Caignard A, Rohrlich PS, Pivot X, Tiberghien P, Zitvogel L, Strominger JL, Borg C.

Blood. 2008 Dec 1;112(12):4420-4. doi: 10.1182/blood-2007-12-126888. Epub 2008 Aug 5.

46.

Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells.

Fourmentraux-Neves E, Jalil A, Da Rocha S, Pichon C, Chouaib S, Bismuth G, Caignard A.

Blood. 2008 Sep 15;112(6):2381-9. doi: 10.1182/blood-2007-12-127779. Epub 2008 Jun 23.

47.

Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15.

Giuliani M, Giron-Michel J, Negrini S, Vacca P, Durali D, Caignard A, Le Bousse-Kerdiles C, Chouaib S, Devocelle A, Bahri R, Durrbach A, Taoufik Y, Ferrini S, Croce M, Mingari MC, Moretta L, Azzarone B.

PLoS One. 2008 May 21;3(5):e2241. doi: 10.1371/journal.pone.0002241.

48.

Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.

Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, Caignard A.

J Immunother. 2008 Apr;31(3):313-23. doi: 10.1097/CJI.0b013e3181609988.

PMID:
18317356
49.

Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.

Kiladjian JJ, Visentin G, Viey E, Chevret S, Eclache V, Stirnemann J, Bourhis JH, Chouaib S, Fenaux P, Caignard A.

Haematologica. 2008 Mar;93(3):381-9. doi: 10.3324/haematol.11812. Epub 2008 Feb 11.

50.

Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes.

Kiladjian JJ, Fenaux P, Caignard A.

Leukemia. 2007 Nov;21(11):2237-9. No abstract available.

PMID:
17957204

Supplemental Content

Loading ...
Support Center